{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T09:15:01Z","timestamp":1788945301953,"version":"build-2803163510"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T00:00:00Z","timestamp":1658707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T00:00:00Z","timestamp":1658707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["398299703"],"award-info":[{"award-number":["398299703"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70113870"],"award-info":[{"award-number":["70113870"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70113871"],"award-info":[{"award-number":["70113871"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"EC | Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["949172"],"award-info":[{"award-number":["949172"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010434","name":"\"la Caixa\" Foundation","doi-asserted-by":"publisher","award":["LCF\/BQ\/EU18\/11650037"],"award-info":[{"award-number":["LCF\/BQ\/EU18\/11650037"]}],"id":[{"id":"10.13039\/100010434","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite advances in multi-modal treatment approaches, clinical outcomes of patients suffering from PAX3-FOXO1 fusion oncogene-expressing alveolar rhabdomyosarcoma (ARMS) remain dismal. Here we show that PAX3-FOXO1-expressing ARMS cells are sensitive to pharmacological ataxia telangiectasia and Rad3 related protein (ATR) inhibition. Expression of PAX3-FOXO1 in muscle progenitor cells is not only sufficient to increase sensitivity to ATR inhibition, but PAX3-FOXO1-expressing rhabdomyosarcoma cells also exhibit increased sensitivity to structurally diverse inhibitors of ATR. Mechanistically, ATR inhibition leads to replication stress exacerbation, decreased BRCA1 phosphorylation and reduced homologous recombination-mediated DNA repair pathway activity. Consequently, ATR inhibitor treatment increases sensitivity of ARMS cells to PARP1 inhibition in vitro, and combined treatment with ATR and PARP1 inhibitors induces complete regression of primary patient-derived ARMS xenografts in vivo. Lastly, a genome-wide CRISPR activation screen (CRISPRa) in combination with transcriptional analyses of ATR inhibitor resistant ARMS cells identifies the RAS-MAPK pathway and its targets, the <jats:italic>FOS<\/jats:italic> gene family, as inducers of resistance to ATR inhibition. Our findings provide a rationale for upcoming biomarker-driven clinical trials of ATR inhibitors in patients suffering from ARMS.<\/jats:p>","DOI":"10.1038\/s41467-022-32023-7","type":"journal-article","created":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T15:08:29Z","timestamp":1658761709000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Therapeutic targeting of ATR in alveolar rhabdomyosarcoma"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2578-3350","authenticated-orcid":false,"given":"Heathcliff","family":"Dorado Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7152-080X","authenticated-orcid":false,"given":"Fabian","family":"Pusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2104-8025","authenticated-orcid":false,"given":"Yi","family":"Bei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9811-445X","authenticated-orcid":false,"given":"Jennifer","family":"von Stebut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glorymar","family":"Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Guillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7451-4982","authenticated-orcid":false,"given":"Koshi","family":"Imami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"G\u00fcrgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Rolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0773-4114","authenticated-orcid":false,"given":"Konstantin","family":"Helmsauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Meyer-Liesener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Timme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Bardinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Chamorro Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1718-1349","authenticated-orcid":false,"given":"Ian C.","family":"MacArthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine Y.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje M.","family":"Wengner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Furth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Lala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3476-8184","authenticated-orcid":false,"given":"Angelika","family":"Eggert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hundsoerfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7049-534X","authenticated-orcid":false,"given":"Marieluise","family":"Kirchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2245-528X","authenticated-orcid":false,"given":"Philipp","family":"Mertins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2454-8751","authenticated-orcid":false,"given":"Matthias","family":"Selbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrej","family":"Lissat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Horst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0671-1201","authenticated-orcid":false,"given":"Johannes H.","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0155-1117","authenticated-orcid":false,"given":"Simone","family":"Spuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoqi","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filemon","family":"Dela Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9091-488X","authenticated-orcid":false,"given":"Andrew L.","family":"Kung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0944-5618","authenticated-orcid":false,"given":"Kerstin","family":"Haase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5189-0793","authenticated-orcid":false,"given":"Michela","family":"DiVirgilio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Scheer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael V.","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1534-778X","authenticated-orcid":false,"given":"Anton G.","family":"Henssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,25]]},"reference":[{"key":"32023_CR1","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1002\/cncr.24465","volume":"115","author":"S Ognjanovic","year":"2009","unstructured":"Ognjanovic, S., Linabery, A. M., Charbonneau, B. & Ross, J. A. Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975\u20132005. Cancer 115, 4218\u20134226 (2009).","journal-title":"Cancer"},{"key":"32023_CR2","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1159\/000132446","volume":"45","author":"EC Douglass","year":"1987","unstructured":"Douglass, E. C. et al. A specific chromosomal abnormality in rhabdomyosarcoma. Cytogenet Cell Genet. 45, 148\u2013155 (1987).","journal-title":"Cytogenet Cell Genet."},{"key":"32023_CR3","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/gcc.2870030611","volume":"3","author":"EC Douglass","year":"1991","unstructured":"Douglass, E. C. et al. Variant translocations of chromosome 13 in alveolar rhabdomyosarcoma. Genes Chromosomes Cancer 3, 480\u2013482 (1991).","journal-title":"Genes Chromosomes Cancer"},{"key":"32023_CR4","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1101\/gad.1244004","volume":"18","author":"C Keller","year":"2004","unstructured":"Keller, C. et al. Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: Cooperativity of Ink4a\/ARF and Trp53 loss of function. Genes Dev. 18, 2614\u20132626 (2004).","journal-title":"Genes Dev."},{"key":"32023_CR5","doi-asserted-by":"publisher","first-page":"e100396","DOI":"10.1371\/journal.pone.0100396","volume":"9","author":"SM Perkins","year":"2014","unstructured":"Perkins, S. M., Shinohara, E. T., DeWees, T. & Frangoul, H. Outcome for children with metastatic solid tumors over the last four decades. PLoS One 9, e100396 (2014).","journal-title":"PLoS One"},{"key":"32023_CR6","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1200\/JCO.1995.13.3.610","volume":"13","author":"W Crist","year":"1995","unstructured":"Crist, W. et al. The third intergroup rhabdomyosarcoma study. J. Clin. Oncol. 13, 610\u2013630 (1995).","journal-title":"J. Clin. Oncol."},{"key":"32023_CR7","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1158\/2159-8290.CD-13-0639","volume":"4","author":"JF Shern","year":"2014","unstructured":"Shern, J. F. et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 4, 216\u2013231 (2014).","journal-title":"Cancer Discov."},{"key":"32023_CR8","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrc3526","volume":"13","author":"NK Cheung","year":"2013","unstructured":"Cheung, N. K. & Dyer, M. A. Neuroblastoma: Developmental biology, cancer genomics, and immunotherapy. Nat. Rev. Cancer 13, 397\u2013411 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"32023_CR9","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1126\/science.278.5340.1064","volume":"278","author":"LH Hartwell","year":"1997","unstructured":"Hartwell, L. H., Szankasi, P., Roberts, C. J., Murray, A. W. & Friend, S. H. Integrating genetic approaches into the discovery of anticancer drugs. Science 278, 1064\u20131068 (1997).","journal-title":"Science"},{"key":"32023_CR10","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917\u2013921 (2005).","journal-title":"Nature"},{"key":"32023_CR11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123\u2013134 (2009).","journal-title":"N. Engl. J. Med."},{"key":"32023_CR12","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1158\/2159-8290.CD-17-1461","volume":"8","author":"P Kotsantis","year":"2018","unstructured":"Kotsantis, P., Petermann, E. & Boulton, S. J. Mechanisms of oncogene-induced replication stress: Jigsaw falling into place. Cancer Discov. 8, 537\u2013555 (2018).","journal-title":"Cancer Discov."},{"key":"32023_CR13","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nrm.2017.67","volume":"18","author":"JC Saldivar","year":"2017","unstructured":"Saldivar, J. C., Cortez, D. & Cimprich, K. A. The essential kinase ATR: Ensuring faithful duplication of a challenging genome. Nat. Rev. Mol. Cell Biol. 18, 622\u2013636 (2017).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"32023_CR14","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/ncb3415","volume":"18","author":"TE Bass","year":"2016","unstructured":"Bass, T. E. et al. ETAA1 acts at stalled replication forks to maintain genome integrity. Nat. Cell Biol. 18, 1185\u20131195 (2016).","journal-title":"Nat. Cell Biol."},{"key":"32023_CR15","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/ncb3422","volume":"18","author":"P Haahr","year":"2016","unstructured":"Haahr, P. et al. Activation of the ATR kinase by the RPA-binding protein ETAA1. Nat. Cell Biol. 18, 1196\u20131207 (2016).","journal-title":"Nat. Cell Biol."},{"key":"32023_CR16","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.molcel.2015.07.029","volume":"59","author":"R Buisson","year":"2015","unstructured":"Buisson, R., Boisvert, J. L., Benes, C. H. & Zou, L. Distinct but concerted roles of ATR, DNA-PK, and Chk1 in countering replication stress during S phase. Mol. Cell 59, 1011\u20131024 (2015).","journal-title":"Mol. Cell"},{"key":"32023_CR17","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1083\/jcb.200104099","volume":"154","author":"C Feijoo","year":"2001","unstructured":"Feijoo, C. et al. Activation of mammalian Chk1 during DNA replication arrest: A role for Chk1 in the intra-S phase checkpoint monitoring replication origin firing. J. Cell Biol. 154, 913\u2013923 (2001).","journal-title":"J. Cell Biol."},{"key":"32023_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ctrv.2013.03.002","volume":"40","author":"E Fokas","year":"2014","unstructured":"Fokas, E. et al. Targeting ATR in DNA damage response and cancer therapeutics. Cancer Treat. Rev. 40, 109\u2013117 (2014).","journal-title":"Cancer Treat. Rev."},{"key":"32023_CR19","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/S0140-6736(15)60373-7","volume":"385","author":"M Kwok","year":"2015","unstructured":"Kwok, M. et al. Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway. Lancet 385, S58 (2015).","journal-title":"Lancet"},{"key":"32023_CR20","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1182\/blood-2015-05-644872","volume":"127","author":"M Kwok","year":"2016","unstructured":"Kwok, M. et al. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells. Blood 127, 582\u2013595 (2016).","journal-title":"Blood"},{"key":"32023_CR21","doi-asserted-by":"publisher","unstructured":"Henssen, A. G. et al. Therapeutic targeting of PGBD5-induced DNA repair dependency in pediatric solid tumors. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.aam9078 (2017).","DOI":"10.1126\/scitranslmed.aam9078"},{"key":"32023_CR22","doi-asserted-by":"publisher","first-page":"873","DOI":"10.4155\/fmc.15.33","volume":"7","author":"KM Foote","year":"2015","unstructured":"Foote, K. M., Lau, A. & Nissink, J. W. Drugging ATR: Progress in the development of specific inhibitors for the treatment of cancer. Future Med. Chem. 7, 873\u2013891 (2015).","journal-title":"Future Med. Chem."},{"key":"32023_CR23","doi-asserted-by":"publisher","first-page":"ra91","DOI":"10.1126\/scisignal.aad8243","volume":"9","author":"I Morgado-Palacin","year":"2016","unstructured":"Morgado-Palacin, I. et al. Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML. Sci. Signal 9, ra91 (2016).","journal-title":"Sci. Signal"},{"key":"32023_CR24","doi-asserted-by":"publisher","first-page":"32396","DOI":"10.18632\/oncotarget.6136","volume":"6","author":"FK Middleton","year":"2015","unstructured":"Middleton, F. K. et al. Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition. Oncotarget 6, 32396\u201332409 (2015).","journal-title":"Oncotarget"},{"key":"32023_CR25","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.1158\/1078-0432.CCR-15-0479","volume":"21","author":"LM Karnitz","year":"2015","unstructured":"Karnitz, L. M. & Zou, L. Molecular pathways: Targeting ATR in Cancer Therapy. Clin. Cancer Res. 21, 4780\u20134785 (2015).","journal-title":"Clin. Cancer Res."},{"key":"32023_CR26","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.molonc.2014.09.012","volume":"9","author":"T Chen","year":"2015","unstructured":"Chen, T. et al. Development of pharmacodynamic biomarkers for ATR inhibitors. Mol. Oncol. 9, 463\u2013472 (2015).","journal-title":"Mol. Oncol."},{"key":"32023_CR27","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s43018-020-00171-8","volume":"2","author":"I Roeschert","year":"2021","unstructured":"Roeschert, I. et al. Combined inhibition of Aurora-A and ATR kinase results in regression of MYCN-amplified neuroblastoma. Nat. Cancer 2, 312\u2013326 (2021).","journal-title":"Nat. Cancer"},{"key":"32023_CR28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/1535-7163.MCT-19-0019","volume":"19","author":"AM Wengner","year":"2020","unstructured":"Wengner, A. M. et al. The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage-inducing or repair-compromising therapies in preclinical cancer models. Mol. Cancer Ther. 19, 26\u201338 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"32023_CR29","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","volume":"11","author":"TA Yap","year":"2021","unstructured":"Yap, T. A. et al. First-in-human trial of the oral ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors. Cancer Discov. 11, 80\u201391 (2021).","journal-title":"Cancer Discov."},{"key":"32023_CR30","doi-asserted-by":"publisher","first-page":"58759","DOI":"10.18632\/oncotarget.11643","volume":"7","author":"M Nieto-Soler","year":"2016","unstructured":"Nieto-Soler, M. et al. Efficacy of ATR inhibitors as single agents in Ewing sarcoma. Oncotarget 7, 58759\u201358767 (2016).","journal-title":"Oncotarget"},{"key":"32023_CR31","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nature25748","volume":"555","author":"A Gorthi","year":"2018","unstructured":"Gorthi, A. et al. EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma. Nature 555, 387\u2013391 (2018).","journal-title":"Nature"},{"key":"32023_CR32","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nrm2450","volume":"9","author":"KA Cimprich","year":"2008","unstructured":"Cimprich, K. A. & Cortez, D. ATR: An essential regulator of genome integrity. Nat. Rev. Mol. Cell Biol. 9, 616\u2013627 (2008).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"32023_CR33","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ncb2897","volume":"16","author":"MK Zeman","year":"2014","unstructured":"Zeman, M. K. & Cimprich, K. A. Causes and consequences of replication stress. Nat. Cell Biol. 16, 2\u20139 (2014).","journal-title":"Nat. Cell Biol."},{"key":"32023_CR34","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nature14493","volume":"522","author":"CZ Zhang","year":"2015","unstructured":"Zhang, C. Z. et al. Chromothripsis from DNA damage in micronuclei. Nature 522, 179\u2013184 (2015).","journal-title":"Nature"},{"key":"32023_CR35","doi-asserted-by":"publisher","first-page":"e18618","DOI":"10.1371\/journal.pone.0018618","volume":"6","author":"B Xu","year":"2011","unstructured":"Xu, B. et al. Replication stress induces micronuclei comprising of aggregated DNA double-strand breaks. PLoS One 6, e18618 (2011).","journal-title":"PLoS One"},{"key":"32023_CR36","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1083\/jcb.60.2.356","volume":"60","author":"LR Gurley","year":"1974","unstructured":"Gurley, L. R., Walters, R. A. & Tobey, R. A. Cell cycle-specific changes in histone phosphorylation associated with cell proliferation and chromosome condensation. J. Cell Biol. 60, 356\u2013364 (1974).","journal-title":"J. Cell Biol."},{"key":"32023_CR37","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1038\/sj.onc.1202973","volume":"18","author":"ND Lakin","year":"1999","unstructured":"Lakin, N. D., Hann, B. C. & Jackson, S. P. The ataxia-telangiectasia related protein ATR mediates DNA-dependent phosphorylation of p53. Oncogene 18, 3989\u20133995 (1999).","journal-title":"Oncogene"},{"key":"32023_CR38","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1074\/mcp.TIR118.000943","volume":"18","author":"K Krug","year":"2019","unstructured":"Krug, K. et al. A curated resource for phosphosite-specific signature analysis. Mol. Cell Proteom. 18, 576\u2013593 (2019).","journal-title":"Mol. Cell Proteom."},{"key":"32023_CR39","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1146\/annurev.cellbio.16.1.89","volume":"16","author":"KH Downing","year":"2000","unstructured":"Downing, K. H. Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. Annu. Rev. Cell Dev. Biol. 16, 89\u2013111 (2000).","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"32023_CR40","doi-asserted-by":"publisher","first-page":"17276","DOI":"10.1074\/jbc.M011681200","volume":"276","author":"M Gatei","year":"2001","unstructured":"Gatei, M. et al. Ataxia telangiectasia mutated (ATM) kinase and ATM and Rad3 related kinase mediate phosphorylation of Brca1 at distinct and overlapping sites. In vivo assessment using phospho-specific antibodies. J. Biol. Chem. 276, 17276\u201317280 (2001).","journal-title":"J. Biol. Chem."},{"key":"32023_CR41","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1074\/jbc.M410873200","volume":"280","author":"CE Helt","year":"2005","unstructured":"Helt, C. E., Cliby, W. A., Keng, P. C., Bambara, R. A. & O\u2019Reilly, M. A. Ataxia telangiectasia mutated (ATM) and ATM and Rad3-related protein exhibit selective target specificities in response to different forms of DNA damage. J. Biol. Chem. 280, 1186\u20131192 (2005).","journal-title":"J. Biol. Chem."},{"key":"32023_CR42","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.bbrc.2010.12.005","volume":"404","author":"Y Kang","year":"2011","unstructured":"Kang, Y. et al. Protein phosphatase 5 is necessary for ATR-mediated DNA repair. Biochem. Biophys. Res Commun. 404, 476\u2013481 (2011).","journal-title":"Biochem. Biophys. Res Commun."},{"key":"32023_CR43","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrc.2015.4","volume":"16","author":"PA Jeggo","year":"2016","unstructured":"Jeggo, P. A., Pearl, L. H. & Carr, A. M. DNA repair, genome stability and cancer: A historical perspective. Nat. Rev. Cancer 16, 35\u201342 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"32023_CR44","doi-asserted-by":"publisher","first-page":"27674","DOI":"10.18632\/oncotarget.4876","volume":"6","author":"JM Beckta","year":"2015","unstructured":"Beckta, J. M. et al. Mutation of the BRCA1 SQ-cluster results in aberrant mitosis, reduced homologous recombination, and a compensatory increase in non-homologous end joining. Oncotarget 6, 27674\u201327687 (2015).","journal-title":"Oncotarget"},{"key":"32023_CR45","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1126\/science.286.5442.1162","volume":"286","author":"D Cortez","year":"1999","unstructured":"Cortez, D., Wang, Y., Qin, J. & Elledge, S. J. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 286, 1162\u20131166 (1999).","journal-title":"Science"},{"key":"32023_CR46","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.1038\/s41388-020-1328-y","volume":"39","author":"RL Lloyd","year":"2020","unstructured":"Lloyd, R. L. et al. Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells. Oncogene 39, 4869\u20134883 (2020).","journal-title":"Oncogene"},{"key":"32023_CR47","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-16-2273","volume":"23","author":"H Kim","year":"2017","unstructured":"Kim, H. et al. Targeting the ATR\/CHK1 Axis with PARP inhibition results in tumor regression. Clin Cancer Res. 23, 3097\u20133108 (2017).","journal-title":"Clin Cancer Res."},{"key":"32023_CR48","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1038\/s41388-017-0081-3","volume":"37","author":"JA Hanna","year":"2018","unstructured":"Hanna, J. A. et al. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma. Oncogene 37, 1991\u20132007 (2018).","journal-title":"Oncogene"},{"key":"32023_CR49","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","volume":"575","author":"N Vasan","year":"2019","unstructured":"Vasan, N., Baselga, J. & Hyman, D. M. A view on drug resistance in cancer. Nature 575, 299\u2013309 (2019).","journal-title":"Nature"},{"key":"32023_CR50","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nature14136","volume":"517","author":"S Konermann","year":"2015","unstructured":"Konermann, S. et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517, 583\u2013588 (2015).","journal-title":"Nature"},{"key":"32023_CR51","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1038\/sj.onc.1204383","volume":"20","author":"E Shaulian","year":"2001","unstructured":"Shaulian, E. & Karin, M. AP-1 in cell proliferation and survival. Oncogene 20, 2390\u20132400 (2001).","journal-title":"Oncogene"},{"key":"32023_CR52","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s001090050063","volume":"74","author":"AJ Whitmarsh","year":"1996","unstructured":"Whitmarsh, A. J. & Davis, R. J. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J. Mol. Med. 74, 589\u2013607 (1996).","journal-title":"J. Mol. Med."},{"key":"32023_CR53","doi-asserted-by":"publisher","first-page":"e1800203","DOI":"10.1002\/pmic.201800203","volume":"18","author":"FNL Vitorino","year":"2018","unstructured":"Vitorino, F. N. L. et al. FGF2 antiproliferative stimulation induces proteomic dynamic changes and high expression of FOSB and JUNB in K-Ras-driven mouse tumor cells. Proteomics 18, e1800203 (2018).","journal-title":"Proteomics"},{"key":"32023_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14294","volume":"8","author":"A Vallejo","year":"2017","unstructured":"Vallejo, A. et al. An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer. Nat. Commun. 8, 14294 (2017).","journal-title":"Nat. Commun."},{"key":"32023_CR55","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1007\/s00018-010-0546-9","volume":"68","author":"MT Tomicic","year":"2011","unstructured":"Tomicic, M. T. et al. Delayed c-Fos activation in human cells triggers XPF induction and an adaptive response to UVC-induced DNA damage and cytotoxicity. Cell Mol. Life Sci. 68, 1785\u20131798 (2011).","journal-title":"Cell Mol. Life Sci."},{"key":"32023_CR56","doi-asserted-by":"publisher","first-page":"8403","DOI":"10.1093\/nar\/gkt635","volume":"41","author":"M Christmann","year":"2013","unstructured":"Christmann, M. & Kaina, B. Transcriptional regulation of human DNA repair genes following genotoxic stress: trigger mechanisms, inducible responses, and genotoxic adaptation. Nucleic Acids Res. 41, 8403\u20138420 (2013).","journal-title":"Nucleic Acids Res."},{"key":"32023_CR57","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ctro.2018.06.001","volume":"12","author":"MT Dillon","year":"2018","unstructured":"Dillon, M. T. et al. PATRIOT: A phase I study to assess the tolerability, safety, and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours. Clin. Transl. Radiat. Oncol. 12, 16\u201320 (2018).","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"32023_CR58","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nchembio.573","volume":"7","author":"PM Reaper","year":"2011","unstructured":"Reaper, P. M. et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat. Chem. Biol. 7, 428\u2013430 (2011).","journal-title":"Nat. Chem. Biol."},{"key":"32023_CR59","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41568-018-0034-3","volume":"18","author":"E Lecona","year":"2018","unstructured":"Lecona, E. & Fernandez-Capetillo, O. Targeting ATR in cancer. Nat. Rev. Cancer 18, 586\u2013595 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"32023_CR60","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1158\/1541-7786.MCR-14-0240","volume":"13","author":"DL Menezes","year":"2015","unstructured":"Menezes, D. L. et al. A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function. Mol. Cancer Res. 13, 120\u2013129 (2015).","journal-title":"Mol. Cancer Res."},{"key":"32023_CR61","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/gcc.20554","volume":"47","author":"GE Mercado","year":"2008","unstructured":"Mercado, G. E. et al. Identification of PAX3-FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: focus on MYCN as a biologically relevant target. Genes Chromosomes Cancer 47, 510\u2013520 (2008).","journal-title":"Genes Chromosomes Cancer"},{"key":"32023_CR62","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1002\/jcp.21726","volume":"219","author":"TA Kato","year":"2009","unstructured":"Kato, T. A., Okayasu, R. & Bedford, J. S. Signatures of DNA double strand breaks produced in irradiated G1 and G2 cells persist into mitosis. J. Cell Physiol. 219, 760\u2013765 (2009).","journal-title":"J. Cell Physiol."},{"key":"32023_CR63","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1083\/jcb.200612047","volume":"176","author":"D Deckbar","year":"2007","unstructured":"Deckbar, D. et al. Chromosome breakage after G2 checkpoint release. J. Cell Biol. 176, 749\u2013755 (2007).","journal-title":"J. Cell Biol."},{"key":"32023_CR64","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/j.celrep.2017.05.031","volume":"19","author":"L Gheghiani","year":"2017","unstructured":"Gheghiani, L., Loew, D., Lombard, B., Mansfeld, J. & Gavet, O. PLK1 activation in late G2 sets up commitment to mitosis. Cell Rep. 19, 2060\u20132073 (2017).","journal-title":"Cell Rep."},{"key":"32023_CR65","doi-asserted-by":"publisher","first-page":"10253","DOI":"10.1158\/0008-5472.CAN-06-2144","volume":"66","author":"RG Sylju\u00e5sen","year":"2006","unstructured":"Sylju\u00e5sen, R. G., Jensen, S., Bartek, J. & Lukas, J. Adaptation to the ionizing radiation-induced G2 checkpoint occurs in human cells and depends on checkpoint kinase 1 and Polo-like kinase 1 kinases. Cancer Res. 66, 10253\u201310257 (2006).","journal-title":"Cancer Res."},{"key":"32023_CR66","doi-asserted-by":"publisher","first-page":"e1004107","DOI":"10.1371\/journal.pgen.1004107","volume":"10","author":"K Kikuchi","year":"2014","unstructured":"Kikuchi, K. et al. Cell-cycle dependent expression of a translocation-mediated fusion oncogene mediates checkpoint adaptation in rhabdomyosarcoma. PLoS Genet. 10, e1004107 (2014).","journal-title":"PLoS Genet."},{"key":"32023_CR67","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1200\/JCO.2017.76.6915","volume":"36","author":"A Thomas","year":"2018","unstructured":"Thomas, A. et al. Phase I study of ATR inhibitor M6620 in combination with topotecan in patients with advanced solid tumors. J. Clin. Oncol. 36, 1594\u20131602 (2018).","journal-title":"J. Clin. Oncol."},{"key":"32023_CR68","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.4161\/cc.28923","volume":"13","author":"J Schulze","year":"2014","unstructured":"Schulze, J. et al. Fos-dependent induction of Chk1 protects osteoblasts from replication stress. Cell Cycle 13, 1980\u20131986 (2014).","journal-title":"Cell Cycle"},{"key":"32023_CR69","doi-asserted-by":"crossref","unstructured":"Arndt, C. A. S. Sarcomas of Bone and Soft Tissues in Children and Adolescents 1 edn 180 (Springer, 2021).","DOI":"10.1007\/978-3-030-51160-9"},{"key":"32023_CR70","doi-asserted-by":"publisher","unstructured":"MacArthur, I. C. et al. Prohibitin promotes de-differentiation and is a potential therapeutic target in neuroblastoma. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.127130 (2019).","DOI":"10.1172\/jci.insight.127130"},{"key":"32023_CR71","doi-asserted-by":"publisher","first-page":"895","DOI":"10.3390\/biology1030895","volume":"1","author":"M Dodt","year":"2012","unstructured":"Dodt, M., Roehr, J. T., Ahmed, R. & Dieterich, C. FLEXBAR-flexible barcode and adapter processing for next-generation sequencing platforms. Biology 1, 895\u2013905 (2012).","journal-title":"Biology"},{"key":"32023_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0554-4","volume":"15","author":"W Li","year":"2014","unstructured":"Li, W. et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens. Genome Biol. 15, 554 (2014).","journal-title":"Genome Biol."},{"key":"32023_CR73","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"32023_CR74","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"32023_CR75","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/978-1-4939-7493-1_17","volume":"1711","author":"L He","year":"2018","unstructured":"He, L. et al. Methods for high-throughput drug combination screening and synergy scoring. Methods Mol. Biol. 1711, 351\u2013398 (2018).","journal-title":"Methods Mol. Biol."},{"key":"32023_CR76","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1101\/gad.13.20.2633","volume":"13","author":"AJ Pierce","year":"1999","unstructured":"Pierce, A. J., Johnson, R. D., Thompson, L. H. & Jasin, M. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev. 13, 2633\u20132638 (1999).","journal-title":"Genes Dev."},{"key":"32023_CR77","doi-asserted-by":"publisher","first-page":"e1000110","DOI":"10.1371\/journal.pgen.1000110","volume":"4","author":"N Bennardo","year":"2008","unstructured":"Bennardo, N., Cheng, A., Huang, N. & Stark, J. M. Alternative-NHEJ is a mechanistically distinct pathway of mammalian chromosome break repair. PLoS Genet. 4, e1000110 (2008).","journal-title":"PLoS Genet."},{"key":"32023_CR78","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1038\/nprot.2007.261","volume":"2","author":"J Rappsilber","year":"2007","unstructured":"Rappsilber, J., Mann, M. & Ishihama, Y. Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat. Protoc. 2, 1896\u20131906 (2007).","journal-title":"Nat. Protoc."},{"key":"32023_CR79","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1021\/pr800305y","volume":"7","author":"Y Kyono","year":"2008","unstructured":"Kyono, Y., Sugiyama, N., Imami, K., Tomita, M. & Ishihama, Y. Successive and selective release of phosphorylated peptides captured by hydroxy acid-modified metal oxide chromatography. J. Proteome Res. 7, 4585\u20134593 (2008).","journal-title":"J. Proteome Res."},{"key":"32023_CR80","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/nbt.1511","volume":"26","author":"J Cox","year":"2008","unstructured":"Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies, and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367\u20131372 (2008).","journal-title":"Nat. Biotechnol."},{"key":"32023_CR81","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1021\/pr101065j","volume":"10","author":"J Cox","year":"2011","unstructured":"Cox, J. et al. Andromeda: A peptide search engine integrated into the MaxQuant environment. J. Proteome Res. 10, 1794\u20131805 (2011).","journal-title":"J. Proteome Res."},{"key":"32023_CR82","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/nprot.2017.147","volume":"13","author":"X Zhang","year":"2018","unstructured":"Zhang, X. et al. Proteome-wide identification of ubiquitin interactions using UbIA-MS. Nat. Protoc. 13, 530\u2013550 (2018).","journal-title":"Nat. Protoc."},{"key":"32023_CR83","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS 16, 284\u2013287 (2012).","journal-title":"OMICS"},{"key":"32023_CR84","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.tranon.2019.09.013","volume":"13","author":"N Timme","year":"2020","unstructured":"Timme, N. et al. Small-molecule dual PLK1 and BRD4 inhibitors are active against preclinical models of pediatric solid tumors. Transl. Oncol. 13, 221\u2013232 (2020).","journal-title":"Transl. Oncol."},{"key":"32023_CR85","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"32023_CR86","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders, S., Pyl, P. T. & Huber, W. HTSeq\u2014A Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166\u2013169 (2015).","journal-title":"Bioinformatics"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32023-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32023-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32023-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T18:30:22Z","timestamp":1669314622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32023-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,25]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["32023"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-32023-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,25]]},"assertion":[{"value":"20 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.M.W. is employed by Bayer AG. A.G.H. has received research funding from Bayer AG. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4297"}}